The HTAC recommends the emergency use of SARS-CoV-2 Vaccine (Vero cell), Inactivated [CoronaVac] (commonly known as Sinovac) to prevent COVID-19 for persons aged 18 to 59 with low risk of exposure to the disease, and within identified priority groups

Sinovac COVID-19 Vaccine under Emergency Use

 The emergency use authorization of the Food and Drug Administration (FDA) (dated 22 February 2021)  allows for timely access of COVID-19 vaccines for Filipinos during the pandemic.  This assures the public that the COVID-19 vaccine has passed the quality, safety, and efficacy criteria. Nevertheless, studies are continuing to determine its long-term efficacy and safety and its potential to reduce COVID-19 transmission.

How does Sinovac COVID-19 Vaccine work?

CoronaVac Vaccine uses inactivated viral particles to expose the body to the virus without the risk of serious disease.

The body reacts by developing protective mechanisms like antibodies. 

Why is Sinovac recommended by HTAC?

Current available data suggests CoronaVac Vaccine may prevent symptomatic COVID-19 and reduce risk for hospital visits for persons aged 18 to 59.

Compared to experience with previous non-COVID vaccines, health authorities worldwide have noted few reported side effects, with no serious injuries or deaths resulting from vaccination. 

Based on existing evidence from ongoing trials, the HTAC considers that the vaccine’s positive health impacts outweigh its short-term risks. 

Other factors informing the HTAC recommendation include potential health, economic, and social benefits in recommending CoronaVac Vaccine. 

As new information emerges, the Council will continue to update its recommendations and provide our policy-makers, health providers, and the Filipino public evidence-based guidance.

Guidance for Health Care Providers:

Evidence summary